[{"address1": "Avinguda de la Generalitat, 152", "address2": "Parc  empresarial Can Sant Joan Sant Cugat del Valles", "city": "Barcelona", "zip": "08174", "country": "Spain", "phone": "34 935 712 200", "fax": "34 938 008 000", "website": "https://www.grifols.com", "industry": "Drug Manufacturers - General", "industryKey": "drug-manufacturers-general", "industryDisp": "Drug Manufacturers - General", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.", "fullTimeEmployees": 23000, "companyOfficers": [{"maxAge": 1, "name": "Mr. Thomas H. Glanzmann", "age": 65, "title": "Executive Chairman", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 2036610, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jose Ignacio  Abia Buenache", "age": 55, "title": "CEO & Director", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alfredo Arroyo Guerra", "age": 65, "title": "CFO & VP", "yearBorn": 1958, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Lluis Pons Gomez", "age": 40, "title": "Senior Vice President of Strategy & COO Office", "yearBorn": 1983, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Nuria Pascual Lape\u00f1a", "age": 59, "title": "VP of Corporate Treasury, Risk Management Investor Relation & Sustainability Officer", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David Ian Bell", "age": 69, "title": "Chief Corporate Development, Legal & Data Protection Officer", "yearBorn": 1954, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maria  Teresa-Rion\u00e9 Llano", "age": 58, "title": "Chief Communications Officer", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Camille  Alpi", "age": 42, "title": "Chief Human Resources & Talent Officer", "yearBorn": 1981, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Vicente  Blanquer Torre", "age": 62, "title": "Chief Quality Officer", "yearBorn": 1961, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sergio Roura Adell", "age": 55, "title": "President of Commercial Tech Support", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 2, "boardRisk": 5, "compensationRisk": 3, "shareHolderRightsRisk": 10, "overallRisk": 4, "governanceEpochDate": 1719619200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 6.3, "open": 6.2, "dayLow": 6.125, "dayHigh": 6.4, "regularMarketPreviousClose": 6.3, "regularMarketOpen": 6.2, "regularMarketDayLow": 6.125, "regularMarketDayHigh": 6.4, "exDividendDate": 1622678400, "fiveYearAvgDividendYield": 2.4, "beta": 0.671, "trailingPE": 63.05, "forwardPE": 4.9257812, "volume": 1319401, "regularMarketVolume": 1319401, "averageVolume": 1211885, "averageVolume10days": 1233330, "averageDailyVolume10Day": 1233330, "bid": 6.27, "ask": 6.32, "bidSize": 200, "askSize": 200, "marketCap": 5124174336, "fiftyTwoWeekLow": 5.3, "fiftyTwoWeekHigh": 12.15, "priceToSalesTrailing12Months": 0.76983535, "fiftyDayAverage": 6.9786, "twoHundredDayAverage": 8.1207, "currency": "USD", "enterpriseValue": 17246507008, "profitMargins": 0.02839, "floatShares": 546431602, "sharesOutstanding": 679091968, "sharesShort": 8218391, "sharesShortPriorMonth": 7952371, "sharesShortPreviousMonthDate": 1715731200, "dateShortInterest": 1718323200, "sharesPercentSharesOut": 0.0121, "heldPercentInstitutions": 0.54673, "shortRatio": 6.55, "impliedSharesOutstanding": 812716032, "bookValue": 8.752, "priceToBook": 0.7204068, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": 189000000, "trailingEps": 0.1, "forwardEps": 1.28, "pegRatio": 0.09, "lastSplitFactor": "2:1", "lastSplitDate": 1451865600, "enterpriseToRevenue": 2.591, "enterpriseToEbitda": 15.975, "52WeekChange": -0.31783783, "SandP52WeekChange": 0.22553468, "lastDividendValue": 0.456, "lastDividendDate": 1622678400, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "GRFS", "underlyingSymbol": "GRFS", "shortName": "Grifols, S.A.", "longName": "Grifols, S.A.", "firstTradeDateEpochUtc": 1307021400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ff4804c3-7e74-32e2-af9a-01ef612b3fc8", "messageBoardId": "finmb_734865", "gmtOffSetMilliseconds": -14400000, "currentPrice": 6.305, "targetHighPrice": 18.73, "targetLowPrice": 13.04, "targetMeanPrice": 15.89, "targetMedianPrice": 15.89, "recommendationMean": 2.4, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 608924032, "totalCashPerShare": 0.897, "ebitda": 1079624960, "totalDebt": 11395699712, "quickRatio": 0.529, "currentRatio": 2.225, "totalRevenue": 6656195072, "debtToEquity": 140.31, "revenuePerShare": 4.901, "returnOnAssets": 0.023020001, "returnOnEquity": 0.03484, "freeCashflow": -1509827712, "operatingCashflow": 104823000, "revenueGrowth": 0.041, "grossMargins": 0.38507998, "ebitdaMargins": 0.16219999, "operatingMargins": 0.14881, "financialCurrency": "EUR", "trailingPegRatio": 0.2056, "__fetch_time": "2024-06-30"}]